Groups

  Plasma

Brain

Liver

Kidney

MDA

MPO

MDA

MPO

MDA

MPO

MDA

MPO

Control group

153.11 ±  7.38

5.63  ± 1.28

83.41 ± 5.86

23.10 ±  3.54

342.1  ±  10.59

15.46 ±  0.75

3.56  ± 0.42

10.21 ± 2.45

Cadmium exposed group

274.30 ±  10.29***

8.44  ± 0.98**

115.20  ± 6.01***

32.45 ±  2.09***

398.5 ±  15.44***

40.22 ± 1.39***

0.884 ± 0.13***

17.50 ±  1.12***

Ceftriaxone plus sulbactam with VRP1034 treated group

210.64 ±  11.52***

6.25  ± 1.99*

103.36  ±  8.28**

29.42 ±  2.63ns

361.87 ±  8.56***

33.98  ±  1.76***

1.96  ± 0.22***

15.26 ±  2.37ns

All data are Mean ± SD of each group. The MDA and MPO levels were expressed in the plasma (μmole/min/ml) whereas in the tissues (μmole/gm tissue). Newman keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant) **p<0.01(significant); *p<0.05 (significant) Nsp>0.05 (non significant).
Table 3: Effect of ceftriaxone plus sulbactam with VRP1034 on oxidative stress parameters in cadmium exposed group after 21 days treatment